LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation
Nano Letters · 04.09.2024 · 24 (35) · 11097-11107
DOI: 10.1021/acs.nanolett.4c03315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 26.08.2024. Verfasst von Yana Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, China. Hauptthemen laut MEDLINE: Fibrosis, Indoles, Kidney. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Renal fibrosis lacks effective nephroprotective drugs in clinical settings due to poor accumulation of therapeutic agents in damaged kidneys, underscoring the urgent need for advanced renal-targeted delivery systems. Herein, we exploited the significantly increased expression of the leucine-rich α-2 glycoprotein 1 (LRG1) protein during renal fibrosis to develop a novel drug delivery system. Our engineered nanocarrier, DENNM, preferentially targets fibrotic kidneys via the decorated ET peptide's high affinity for LRG1. Once internalized by damaged renal cells, DENNM releases its encapsulated nintedanib, triggered by the active caspase-3 protease, disrupting the nanomedicine's structural integrity. The released nintedanib effectively reduces the level of expression of the extracellular matrix and impedes the progression of renal fibrosis by inhibiting the transforming growth factor-β (TGF-β)-Smad2/3 pathway. Our comprehensive in vitro and in vivo studies validate DENNM's antifibrotic efficacy, emphasizing LRG1's potential in renal targeted drug delivery and introducing an innovative approach to nanomedicine for treating renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, China.
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
ORCID-Profile: Yingqiu Qi
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Wang, L., Yang, X., Fan, L., Li, Y., Zhu, F., Zhu, A., Du, S., Min, H., & Qi, Y. (2024). LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation. Nano Letters, 24(35), 11097-11107. https://doi.org/10.1021/acs.nanolett.4c03315
Vancouver
Zhang Y, Wang L, Yang X, Fan L, Li Y, Zhu F, et al. LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation. Nano Letters. 2024;24(35):11097-11107. doi:10.1021/acs.nanolett.4c03315
BibTeX
@article{Zhang2024,
author = {Zhang, Yana and Wang, Longdi and Yang, Xi and Fan, Linyao and Li, Yongzheng and Zhu, Furong and Zhu, Anying and Du, Shengnan and Min, Huan and Qi, Yingqiu},
title = {LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation},
journal = {Nano Letters},
year = {2024},
volume = {24},
number = {35},
pages = {11097--11107},
doi = {10.1021/acs.nanolett.4c03315}
}
EUVIMED